Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTA-TOC and 177Lu-DOTA-TOC in Metastasized Neuroendocrine Tumors
NCT00978211Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Sep 1997
- Primary completion
- Sep 2013
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 edotreotide, lutetium Lu 177-edotreotide in neuroendocrine tumors (NETs), sponsored by University Hospital Basel. Started Sep 1997; status: completed.
02
Drugs
yttrium-90 edotreotidelutetium Lu 177-edotreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00978211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00978211.